Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 18-Sep-24
Select bar for recommendation details.
Recommendations18-Sep-24
Buy2
Outperform6
Hold5
Sell0
Strong Sell1

Share price forecast in USD

The 8 analysts offering 12 month price targets for Resmed Inc have a median target of 227.50, with a high estimate of 251.00 and a low estimate of 180.00. The median estimate represents a -4.42% decrease from the last price of 238.03.
High5.4%251.00
Med-4.4%227.50
Low-24.4%180.00

Dividends in USD

In 2024, Resmed Inc reported a dividend of 1.92 USD, which represents a 9.09% increase over last year. The 7 analysts covering the company expect dividends of 2.29 USD for the upcoming fiscal year, an increase of 19.32%.
Div growth (TTM)9.09%
More ▼

Earnings history & estimates in USD

On Aug 01, 2024, Resmed Inc reported 4th quarter 2024 earnings of 2.08 per share. This result was in line with the consensus of the 10 analysts following the company and exceeded last year's 4th quarter results by 30.00%.
The next earnings announcement is expected on Oct 24, 2024.
Average growth rate+7.02%
Resmed Inc reported annual 2024 earnings of 7.72 per share on Aug 01, 2024.
Average growth rate+12.93%
More ▼

Revenue history & estimates in USD

ResMed Inc. had 4th quarter 2024 revenues of 1.22bn. This bettered the 1.22bn consensus of the 13 analysts covering the company. This was 28.72% above the prior year's 4th quarter results.
Average growth rate+2.21%
ResMed Inc. had revenues for the full year 2024 of 4.69bn. This was 10.95% above the prior year's results.
Average growth rate+12.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.